-
Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study
•
China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide drug, has been approved in China for a clinical study in COVID-19 infection. Drug Mechanism and DevelopmentThe Category 1 drug candidate, co-developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences, can play…
-
Henan Celnovte Biotechnology Raises RMB 100M in New Financing Round
•
China-based Henan Celnovte Biotechnology Co., Ltd, a tumor in vitro diagnostic reagents (IVDs) and instruments maker, reportedly raised RMB 100 million (USD 14.15 million) via another financing round. Investors included Puhua Capital, Henan Hi-Tech Venture Capital, Zhengzhou High Tech Industry Investment Fund, and Zhong Yuan Lian Chuang Capital. Company Background…
-
Clover Biopharmaceuticals’ SCB-2019 Vaccine Reduces Household Transmission of COVID-19
•
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase II/III clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants. Trial Results and ImplicationsThere…
-
Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in a Phase II clinical study for ASC40 (denifanstat). The molecule is set to be assessed in treating moderate to severe acne. The study is currently still blinded. Study Design and ObjectivesThe randomized, double-blind, placebo-controlled, multicenter…
-
Ascletis Pharma’s COVID-19 Drug Candidate ASC11 Accepted for Review by NMPA
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its Investigational New Drug (IND) filing for ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19, has been accepted for review by the National Medical Products Administration (NMPA). Drug Profile and PotencyIn antiviral cellular assays with infectious…
-
Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline
•
China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed amount of money. The proceeds will be used to accelerate Investigational New Drug (IND) filings and clinical trials for its two pre-clinical candidate drugs. Company Focus and PipelinePolymed Bio specializes in the development of bifunctional…
-
Fosun Pharma Weighs Sale of India’s Gland Pharma Amid Market Interest
•
Shanghai Fosun Pharmaceutical Group Co. (HKG: 2196, SHA: 600196) is reportedly considering the sale of its India-based majority-owned Gland Pharma Ltd (BOM: 543245), according to a Bloomberg report. This follows interest from potential buyers, as cited by insiders. Market Interest and Early StagesFosun is reportedly in the early stages of…
-
Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million
•
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd (BOM: 543245), plans to acquire privately held French pharmaceutical firm Cenexi for EUR 120 million (USD 124 million). In addition to the purchase price, Fosun Pharma will provide shareholder loans to Cenexi, with the total…
-
Luye Pharma Initiates Phase II Study for LY 03014 in China
•
China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase II clinical study for its Category 1 drug candidate, LY 03014. The multi-center, randomized, double-blind, placebo-controlled, and positive drug parallel control study aims to assess the preliminary efficacy and safety of the drug in treating…
-
Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement
•
China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities Regulatory Commission (CSRC) to conduct a private placement of 70 million shares. The company plans to raise RMB 2.5 billion (USD 350 million) through this transaction, with proceeds allocated towards the Phase 1 construction of…
-
Frontier Biotechnologies Partners with CASAPC for AIDS Prevention in China
•
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced a collaboration agreement with the Chinese Association of STD and AIDS Prevention and Control (CASAPC) to facilitate precision prevention and control of AIDS in China. The partnership aims to enhance the effectiveness of existing measures and better allocate resources for combating the…
-
Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang
•
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in a head-to-head bridging study for its programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The study is evaluating serplulimab as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) against Roche’s PD-L1 inhibitor Tecentriq (atezolizumab), the…
-
JancsiTech Raises Tens of Millions in Angel Round Led by Yuanbio Venture Capital
•
JancsiTech, a precision nuclear medicine specialist based in Shenzhen, has reportedly raised “tens of millions” of renminbi in an angel financing round led by Yuanbio Venture Capital. Existing investor Sequoia Capital China also participated in the round. The proceeds will be directed towards research and development, innovation of intelligent medical…
-
FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment
•
US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA) for poziotinib, a treatment for previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations, received a complete response letter (CRL) from the US FDA. The CRL cited…
-
Sino Biological to Invest RMB 1 Billion in Beijing Bio-Pharmaceutical Park
•
Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140 million) to create a one-stop biological reagent and technology service platform. The initiative also includes the development of a comprehensive bio-pharmaceutical innovation service park in the Beijing Economic-Technological Development Area. As of the announcement date,…
-
Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment
•
China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine (LY03005) in China. The extended-release treatment for depression has received its first prescriptions and is being launched through a multi-channel strategy that includes hospitals, pharmacies, and online platforms. Drug Profile and MechanismToludesvenlafaxine is a new…
-
Hope Medicine Gains Global Approval for Phase II Trial of HMI-115
•
China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II clinical study for its monoclonal antibody (mAb) HMI-115, targeting the prolactin receptor (PRL R). The drug is being evaluated as a treatment for endometriosis, a condition that affects many women worldwide. This potential first-in-class (FIC)…
-
Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline
•
Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move is expected to significantly expand Full-Life’s pipeline, including two compounds nearing clinical trials, provide a second innovative peptide-focused discovery platform, and leverage its Radio Technology manufacturing and logistics platforms to advance compounds into clinical development.…
-
I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies
•
China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to accelerate biomarker-driven clinical studies and explore the cutting edge of companion diagnostics (CDx) development. Financial details of the partnership were not disclosed. Clinical and Development ContextWith the deepening of research on tumor pathogenesis, immunotherapy, particularly…
-
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
•
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a pre-IPO financing round. The funding was led by Gree Financial Investment and KingRay Capital, with additional participation from Efung Capital, China Medical System Holdings (CMS; HKG: 0867), Wuxi Guolian Development (Group), and other investors. Technology…
